nodes	percent_of_prediction	percent_of_DWPC	metapath
Duloxetine—CYP1A2—Imiquimod—skin cancer	0.193	0.375	CbGbCtD
Duloxetine—CYP1A2—Vemurafenib—skin cancer	0.106	0.206	CbGbCtD
Duloxetine—CYP2D6—Vemurafenib—skin cancer	0.087	0.169	CbGbCtD
Duloxetine—CYP1A2—Dacarbazine—skin cancer	0.0809	0.158	CbGbCtD
Duloxetine—CYP1A2—Fluorouracil—skin cancer	0.0474	0.0924	CbGbCtD
Duloxetine—NPY1R—nerve—skin cancer	0.0112	0.165	CbGeAlD
Duloxetine—NPY1R—nipple—skin cancer	0.00637	0.0939	CbGeAlD
Duloxetine—SLC6A3—nerve—skin cancer	0.00472	0.0696	CbGeAlD
Duloxetine—SLC6A2—nerve—skin cancer	0.00381	0.0561	CbGeAlD
Duloxetine—HTR2A—hindlimb—skin cancer	0.00377	0.0555	CbGeAlD
Duloxetine—NPY1R—mammalian vulva—skin cancer	0.00372	0.0548	CbGeAlD
Duloxetine—HTR2A—appendage—skin cancer	0.00323	0.0476	CbGeAlD
Duloxetine—NPY1R—female reproductive system—skin cancer	0.00319	0.0469	CbGeAlD
Duloxetine—NPY1R—head—skin cancer	0.00266	0.0392	CbGeAlD
Duloxetine—HTR2A—nerve—skin cancer	0.00229	0.0337	CbGeAlD
Duloxetine—HTR2A—endothelium—skin cancer	0.00195	0.0287	CbGeAlD
Duloxetine—HTR6—head—skin cancer	0.00187	0.0276	CbGeAlD
Duloxetine—NPY1R—lymph node—skin cancer	0.00186	0.0275	CbGeAlD
Duloxetine—HTR2A—blood vessel—skin cancer	0.0018	0.0265	CbGeAlD
Duloxetine—CYP1A2—nipple—skin cancer	0.00166	0.0245	CbGeAlD
Duloxetine—HTR2C—female reproductive system—skin cancer	0.0013	0.0191	CbGeAlD
Duloxetine—HTR2A—neck—skin cancer	0.00129	0.019	CbGeAlD
Duloxetine—SLC6A4—female reproductive system—skin cancer	0.00123	0.0181	CbGeAlD
Duloxetine—SLC6A3—head—skin cancer	0.00112	0.0165	CbGeAlD
Duloxetine—HTR2C—head—skin cancer	0.00108	0.016	CbGeAlD
Duloxetine—SLC6A2—female reproductive system—skin cancer	0.00108	0.0159	CbGeAlD
Duloxetine—SLC6A4—head—skin cancer	0.00103	0.0151	CbGeAlD
Duloxetine—HTR2A—connective tissue—skin cancer	0.000922	0.0136	CbGeAlD
Duloxetine—SLC6A2—head—skin cancer	0.000904	0.0133	CbGeAlD
Duloxetine—HTR2A—epithelium—skin cancer	0.000876	0.0129	CbGeAlD
Duloxetine—NPY1R—Peptide GPCRs—MC1R—skin cancer	0.000807	0.0662	CbGpPWpGaD
Duloxetine—SLC6A4—Synaptic Vesicle Pathway—SYP—skin cancer	0.000777	0.0638	CbGpPWpGaD
Duloxetine—HTR2A—female reproductive system—skin cancer	0.00065	0.00958	CbGeAlD
Duloxetine—SLC6A2—lymph node—skin cancer	0.000633	0.00932	CbGeAlD
Duloxetine—CYP2D6—female reproductive system—skin cancer	0.000592	0.00873	CbGeAlD
Duloxetine—HTR2A—head—skin cancer	0.000543	0.008	CbGeAlD
Duloxetine—SLC6A3—Dopaminergic Neurogenesis—GLI2—skin cancer	0.00052	0.0427	CbGpPWpGaD
Duloxetine—CYP2D6—head—skin cancer	0.000495	0.00729	CbGeAlD
Duloxetine—SLC6A3—Dopaminergic Neurogenesis—GLI1—skin cancer	0.000489	0.0401	CbGpPWpGaD
Duloxetine—Alopecia—Temozolomide—skin cancer	0.000439	0.00108	CcSEcCtD
Duloxetine—Chest pain—Bleomycin—skin cancer	0.000436	0.00107	CcSEcCtD
Duloxetine—Myalgia—Bleomycin—skin cancer	0.000436	0.00107	CcSEcCtD
Duloxetine—Orthostatic hypotension—Docetaxel—skin cancer	0.000436	0.00107	CcSEcCtD
Duloxetine—Abdominal pain upper—Docetaxel—skin cancer	0.000436	0.00107	CcSEcCtD
Duloxetine—Rash—Vemurafenib—skin cancer	0.000435	0.00107	CcSEcCtD
Duloxetine—Mental disorder—Temozolomide—skin cancer	0.000435	0.00107	CcSEcCtD
Duloxetine—Dermatitis—Vemurafenib—skin cancer	0.000435	0.00107	CcSEcCtD
Duloxetine—Hypersensitivity—Imiquimod—skin cancer	0.000434	0.00107	CcSEcCtD
Duloxetine—Headache—Vemurafenib—skin cancer	0.000433	0.00106	CcSEcCtD
Duloxetine—Malnutrition—Temozolomide—skin cancer	0.000432	0.00106	CcSEcCtD
Duloxetine—Erythema—Temozolomide—skin cancer	0.000432	0.00106	CcSEcCtD
Duloxetine—Breast disorder—Docetaxel—skin cancer	0.000431	0.00106	CcSEcCtD
Duloxetine—Discomfort—Bleomycin—skin cancer	0.000431	0.00106	CcSEcCtD
Duloxetine—Malaise—Dactinomycin—skin cancer	0.000431	0.00106	CcSEcCtD
Duloxetine—Cramp muscle—Docetaxel—skin cancer	0.00043	0.00106	CcSEcCtD
Duloxetine—Aspartate aminotransferase increased—Docetaxel—skin cancer	0.00043	0.00106	CcSEcCtD
Duloxetine—Leukopenia—Dactinomycin—skin cancer	0.000428	0.00105	CcSEcCtD
Duloxetine—Nasopharyngitis—Docetaxel—skin cancer	0.000427	0.00105	CcSEcCtD
Duloxetine—Dysgeusia—Temozolomide—skin cancer	0.000423	0.00104	CcSEcCtD
Duloxetine—Asthenia—Imiquimod—skin cancer	0.000423	0.00104	CcSEcCtD
Duloxetine—Confusional state—Bleomycin—skin cancer	0.000422	0.00104	CcSEcCtD
Duloxetine—Alanine aminotransferase increased—Docetaxel—skin cancer	0.000421	0.00104	CcSEcCtD
Duloxetine—Oedema—Bleomycin—skin cancer	0.000418	0.00103	CcSEcCtD
Duloxetine—Anaphylactic shock—Bleomycin—skin cancer	0.000418	0.00103	CcSEcCtD
Duloxetine—Back pain—Temozolomide—skin cancer	0.000418	0.00103	CcSEcCtD
Duloxetine—Pruritus—Imiquimod—skin cancer	0.000417	0.00103	CcSEcCtD
Duloxetine—Infection—Bleomycin—skin cancer	0.000416	0.00102	CcSEcCtD
Duloxetine—Dysphagia—Docetaxel—skin cancer	0.000413	0.00102	CcSEcCtD
Duloxetine—Nausea—Vemurafenib—skin cancer	0.00041	0.00101	CcSEcCtD
Duloxetine—Thrombocytopenia—Bleomycin—skin cancer	0.00041	0.00101	CcSEcCtD
Duloxetine—Arrhythmia—Fluorouracil—skin cancer	0.000409	0.00101	CcSEcCtD
Duloxetine—Vision blurred—Temozolomide—skin cancer	0.000408	0.001	CcSEcCtD
Duloxetine—Myalgia—Dactinomycin—skin cancer	0.000407	0.001	CcSEcCtD
Duloxetine—Tremor—Temozolomide—skin cancer	0.000405	0.000997	CcSEcCtD
Duloxetine—Alopecia—Fluorouracil—skin cancer	0.000404	0.000995	CcSEcCtD
Duloxetine—Diarrhoea—Imiquimod—skin cancer	0.000403	0.000992	CcSEcCtD
Duloxetine—Discomfort—Dactinomycin—skin cancer	0.000402	0.00099	CcSEcCtD
Duloxetine—Ill-defined disorder—Temozolomide—skin cancer	0.000401	0.000987	CcSEcCtD
Duloxetine—Anaemia—Temozolomide—skin cancer	0.0004	0.000983	CcSEcCtD
Duloxetine—Anorexia—Bleomycin—skin cancer	0.000399	0.000981	CcSEcCtD
Duloxetine—Erythema—Fluorouracil—skin cancer	0.000398	0.00098	CcSEcCtD
Duloxetine—Agitation—Temozolomide—skin cancer	0.000397	0.000978	CcSEcCtD
Duloxetine—Angioedema—Temozolomide—skin cancer	0.000395	0.000972	CcSEcCtD
Duloxetine—Oedema—Dactinomycin—skin cancer	0.00039	0.00096	CcSEcCtD
Duloxetine—Malaise—Temozolomide—skin cancer	0.00039	0.00096	CcSEcCtD
Duloxetine—Dizziness—Imiquimod—skin cancer	0.000389	0.000958	CcSEcCtD
Duloxetine—Vertigo—Temozolomide—skin cancer	0.000388	0.000956	CcSEcCtD
Duloxetine—Infection—Dactinomycin—skin cancer	0.000388	0.000954	CcSEcCtD
Duloxetine—Leukopenia—Temozolomide—skin cancer	0.000387	0.000952	CcSEcCtD
Duloxetine—Palpitations—Temozolomide—skin cancer	0.000382	0.00094	CcSEcCtD
Duloxetine—Thrombocytopenia—Dactinomycin—skin cancer	0.000382	0.00094	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000381	0.000938	CcSEcCtD
Duloxetine—NPY1R—Peptide ligand-binding receptors—MC1R—skin cancer	0.000379	0.0311	CbGpPWpGaD
Duloxetine—Cough—Temozolomide—skin cancer	0.000377	0.000929	CcSEcCtD
Duloxetine—Paraesthesia—Bleomycin—skin cancer	0.000376	0.000924	CcSEcCtD
Duloxetine—Weight increased—Docetaxel—skin cancer	0.000376	0.000924	CcSEcCtD
Duloxetine—Vision blurred—Fluorouracil—skin cancer	0.000375	0.000924	CcSEcCtD
Duloxetine—Convulsion—Temozolomide—skin cancer	0.000375	0.000922	CcSEcCtD
Duloxetine—Vomiting—Imiquimod—skin cancer	0.000374	0.000921	CcSEcCtD
Duloxetine—Weight decreased—Docetaxel—skin cancer	0.000373	0.000919	CcSEcCtD
Duloxetine—Hypertension—Temozolomide—skin cancer	0.000373	0.000919	CcSEcCtD
Duloxetine—Anorexia—Dactinomycin—skin cancer	0.000372	0.000915	CcSEcCtD
Duloxetine—Rash—Imiquimod—skin cancer	0.000371	0.000914	CcSEcCtD
Duloxetine—Dermatitis—Imiquimod—skin cancer	0.000371	0.000913	CcSEcCtD
Duloxetine—Headache—Imiquimod—skin cancer	0.000369	0.000908	CcSEcCtD
Duloxetine—Anaemia—Fluorouracil—skin cancer	0.000368	0.000906	CcSEcCtD
Duloxetine—Myalgia—Temozolomide—skin cancer	0.000368	0.000906	CcSEcCtD
Duloxetine—Arthralgia—Temozolomide—skin cancer	0.000368	0.000906	CcSEcCtD
Duloxetine—Infestation NOS—Docetaxel—skin cancer	0.000368	0.000906	CcSEcCtD
Duloxetine—Infestation—Docetaxel—skin cancer	0.000368	0.000906	CcSEcCtD
Duloxetine—Anxiety—Temozolomide—skin cancer	0.000367	0.000903	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000366	0.0009	CcSEcCtD
Duloxetine—Stevens-Johnson syndrome—Docetaxel—skin cancer	0.000365	0.000898	CcSEcCtD
Duloxetine—Discomfort—Temozolomide—skin cancer	0.000364	0.000895	CcSEcCtD
Duloxetine—Decreased appetite—Bleomycin—skin cancer	0.000364	0.000895	CcSEcCtD
Duloxetine—Acute coronary syndrome—Docetaxel—skin cancer	0.000363	0.000893	CcSEcCtD
Duloxetine—Renal failure—Docetaxel—skin cancer	0.000362	0.00089	CcSEcCtD
Duloxetine—Myocardial infarction—Docetaxel—skin cancer	0.000361	0.000888	CcSEcCtD
Duloxetine—Dry mouth—Temozolomide—skin cancer	0.00036	0.000886	CcSEcCtD
Duloxetine—Jaundice—Docetaxel—skin cancer	0.000359	0.000883	CcSEcCtD
Duloxetine—Stomatitis—Docetaxel—skin cancer	0.000359	0.000883	CcSEcCtD
Duloxetine—Pain—Bleomycin—skin cancer	0.000358	0.00088	CcSEcCtD
Duloxetine—Conjunctivitis—Docetaxel—skin cancer	0.000358	0.00088	CcSEcCtD
Duloxetine—Leukopenia—Fluorouracil—skin cancer	0.000357	0.000878	CcSEcCtD
Duloxetine—Confusional state—Temozolomide—skin cancer	0.000356	0.000876	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000355	0.000875	CcSEcCtD
Duloxetine—SLC6A3—Dopaminergic Neurogenesis—SHH—skin cancer	0.000353	0.029	CbGpPWpGaD
Duloxetine—Oedema—Temozolomide—skin cancer	0.000353	0.000868	CcSEcCtD
Duloxetine—Anaphylactic shock—Temozolomide—skin cancer	0.000353	0.000868	CcSEcCtD
Duloxetine—Infection—Temozolomide—skin cancer	0.000351	0.000863	CcSEcCtD
Duloxetine—Nausea—Imiquimod—skin cancer	0.00035	0.000861	CcSEcCtD
Duloxetine—Hepatobiliary disease—Docetaxel—skin cancer	0.000348	0.000856	CcSEcCtD
Duloxetine—Epistaxis—Docetaxel—skin cancer	0.000347	0.000854	CcSEcCtD
Duloxetine—Nervous system disorder—Temozolomide—skin cancer	0.000346	0.000852	CcSEcCtD
Duloxetine—Thrombocytopenia—Temozolomide—skin cancer	0.000346	0.00085	CcSEcCtD
Duloxetine—Convulsion—Fluorouracil—skin cancer	0.000345	0.000849	CcSEcCtD
Duloxetine—Feeling abnormal—Bleomycin—skin cancer	0.000345	0.000848	CcSEcCtD
Duloxetine—Skin disorder—Temozolomide—skin cancer	0.000343	0.000844	CcSEcCtD
Duloxetine—Hyperhidrosis—Temozolomide—skin cancer	0.000341	0.00084	CcSEcCtD
Duloxetine—Chest pain—Fluorouracil—skin cancer	0.000339	0.000835	CcSEcCtD
Duloxetine—Myalgia—Fluorouracil—skin cancer	0.000339	0.000835	CcSEcCtD
Duloxetine—Decreased appetite—Dactinomycin—skin cancer	0.000339	0.000835	CcSEcCtD
Duloxetine—Fatigue—Dactinomycin—skin cancer	0.000336	0.000828	CcSEcCtD
Duloxetine—Anorexia—Temozolomide—skin cancer	0.000336	0.000828	CcSEcCtD
Duloxetine—Discomfort—Fluorouracil—skin cancer	0.000335	0.000825	CcSEcCtD
Duloxetine—Pain—Dactinomycin—skin cancer	0.000334	0.000821	CcSEcCtD
Duloxetine—Urticaria—Bleomycin—skin cancer	0.000332	0.000818	CcSEcCtD
Duloxetine—Haemoglobin—Docetaxel—skin cancer	0.000332	0.000817	CcSEcCtD
Duloxetine—Body temperature increased—Bleomycin—skin cancer	0.000331	0.000814	CcSEcCtD
Duloxetine—Haemorrhage—Docetaxel—skin cancer	0.00033	0.000813	CcSEcCtD
Duloxetine—Hepatitis—Docetaxel—skin cancer	0.00033	0.000813	CcSEcCtD
Duloxetine—Hypoaesthesia—Docetaxel—skin cancer	0.000329	0.000809	CcSEcCtD
Duloxetine—Confusional state—Fluorouracil—skin cancer	0.000328	0.000807	CcSEcCtD
Duloxetine—Pharyngitis—Docetaxel—skin cancer	0.000328	0.000807	CcSEcCtD
Duloxetine—Urinary tract disorder—Docetaxel—skin cancer	0.000326	0.000803	CcSEcCtD
Duloxetine—Oedema peripheral—Docetaxel—skin cancer	0.000325	0.000801	CcSEcCtD
Duloxetine—Anaphylactic shock—Fluorouracil—skin cancer	0.000325	0.0008	CcSEcCtD
Duloxetine—Oedema—Fluorouracil—skin cancer	0.000325	0.0008	CcSEcCtD
Duloxetine—Connective tissue disorder—Docetaxel—skin cancer	0.000325	0.000799	CcSEcCtD
Duloxetine—Urethral disorder—Docetaxel—skin cancer	0.000324	0.000797	CcSEcCtD
Duloxetine—Infection—Fluorouracil—skin cancer	0.000323	0.000795	CcSEcCtD
Duloxetine—Feeling abnormal—Dactinomycin—skin cancer	0.000322	0.000791	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000322	0.000791	CcSEcCtD
Duloxetine—Insomnia—Temozolomide—skin cancer	0.000319	0.000785	CcSEcCtD
Duloxetine—Gastrointestinal pain—Dactinomycin—skin cancer	0.000319	0.000785	CcSEcCtD
Duloxetine—Nervous system disorder—Fluorouracil—skin cancer	0.000319	0.000785	CcSEcCtD
Duloxetine—Thrombocytopenia—Fluorouracil—skin cancer	0.000318	0.000783	CcSEcCtD
Duloxetine—Visual impairment—Docetaxel—skin cancer	0.000318	0.000783	CcSEcCtD
Duloxetine—Tachycardia—Fluorouracil—skin cancer	0.000317	0.000781	CcSEcCtD
Duloxetine—Paraesthesia—Temozolomide—skin cancer	0.000317	0.00078	CcSEcCtD
Duloxetine—Somnolence—Temozolomide—skin cancer	0.000314	0.000772	CcSEcCtD
Duloxetine—Erythema multiforme—Docetaxel—skin cancer	0.000312	0.000769	CcSEcCtD
Duloxetine—Dyspepsia—Temozolomide—skin cancer	0.000311	0.000764	CcSEcCtD
Duloxetine—Anorexia—Fluorouracil—skin cancer	0.00031	0.000763	CcSEcCtD
Duloxetine—Eye disorder—Docetaxel—skin cancer	0.000309	0.00076	CcSEcCtD
Duloxetine—Abdominal pain—Dactinomycin—skin cancer	0.000308	0.000759	CcSEcCtD
Duloxetine—Body temperature increased—Dactinomycin—skin cancer	0.000308	0.000759	CcSEcCtD
Duloxetine—Hypersensitivity—Bleomycin—skin cancer	0.000308	0.000758	CcSEcCtD
Duloxetine—Decreased appetite—Temozolomide—skin cancer	0.000307	0.000755	CcSEcCtD
Duloxetine—Flushing—Docetaxel—skin cancer	0.000307	0.000754	CcSEcCtD
Duloxetine—Cardiac disorder—Docetaxel—skin cancer	0.000307	0.000754	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Temozolomide—skin cancer	0.000305	0.00075	CcSEcCtD
Duloxetine—Fatigue—Temozolomide—skin cancer	0.000304	0.000749	CcSEcCtD
Duloxetine—Constipation—Temozolomide—skin cancer	0.000302	0.000743	CcSEcCtD
Duloxetine—Pain—Temozolomide—skin cancer	0.000302	0.000743	CcSEcCtD
Duloxetine—Asthenia—Bleomycin—skin cancer	0.0003	0.000739	CcSEcCtD
Duloxetine—Angiopathy—Docetaxel—skin cancer	0.0003	0.000738	CcSEcCtD
Duloxetine—Immune system disorder—Docetaxel—skin cancer	0.000298	0.000734	CcSEcCtD
Duloxetine—Mediastinal disorder—Docetaxel—skin cancer	0.000298	0.000733	CcSEcCtD
Duloxetine—NPY1R—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	0.000297	0.0244	CbGpPWpGaD
Duloxetine—Chills—Docetaxel—skin cancer	0.000296	0.000729	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000296	0.000729	CcSEcCtD
Duloxetine—Pruritus—Bleomycin—skin cancer	0.000296	0.000728	CcSEcCtD
Duloxetine—Arrhythmia—Docetaxel—skin cancer	0.000295	0.000726	CcSEcCtD
Duloxetine—Insomnia—Fluorouracil—skin cancer	0.000294	0.000724	CcSEcCtD
Duloxetine—Paraesthesia—Fluorouracil—skin cancer	0.000292	0.000718	CcSEcCtD
Duloxetine—Alopecia—Docetaxel—skin cancer	0.000292	0.000718	CcSEcCtD
Duloxetine—Feeling abnormal—Temozolomide—skin cancer	0.000291	0.000716	CcSEcCtD
Duloxetine—Mental disorder—Docetaxel—skin cancer	0.000289	0.000712	CcSEcCtD
Duloxetine—Somnolence—Fluorouracil—skin cancer	0.000289	0.000711	CcSEcCtD
Duloxetine—Gastrointestinal pain—Temozolomide—skin cancer	0.000289	0.00071	CcSEcCtD
Duloxetine—Erythema—Docetaxel—skin cancer	0.000288	0.000708	CcSEcCtD
Duloxetine—Malnutrition—Docetaxel—skin cancer	0.000288	0.000708	CcSEcCtD
Duloxetine—Hypersensitivity—Dactinomycin—skin cancer	0.000287	0.000707	CcSEcCtD
Duloxetine—Dyspepsia—Fluorouracil—skin cancer	0.000286	0.000704	CcSEcCtD
Duloxetine—Decreased appetite—Fluorouracil—skin cancer	0.000283	0.000696	CcSEcCtD
Duloxetine—Dysgeusia—Docetaxel—skin cancer	0.000282	0.000693	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000281	0.000691	CcSEcCtD
Duloxetine—Urticaria—Temozolomide—skin cancer	0.00028	0.00069	CcSEcCtD
Duloxetine—Asthenia—Dactinomycin—skin cancer	0.00028	0.000689	CcSEcCtD
Duloxetine—Abdominal pain—Temozolomide—skin cancer	0.000279	0.000687	CcSEcCtD
Duloxetine—Body temperature increased—Temozolomide—skin cancer	0.000279	0.000687	CcSEcCtD
Duloxetine—Back pain—Docetaxel—skin cancer	0.000278	0.000684	CcSEcCtD
Duloxetine—Pain—Fluorouracil—skin cancer	0.000278	0.000684	CcSEcCtD
Duloxetine—Muscle spasms—Docetaxel—skin cancer	0.000276	0.00068	CcSEcCtD
Duloxetine—HTR6—Serotonin Receptor 4/6/7 and NR3C Signaling—BRAF—skin cancer	0.000271	0.0223	CbGpPWpGaD
Duloxetine—NPY1R—GPCR ligand binding—PTCH2—skin cancer	0.000268	0.022	CbGpPWpGaD
Duloxetine—Feeling abnormal—Fluorouracil—skin cancer	0.000268	0.000659	CcSEcCtD
Duloxetine—Diarrhoea—Dactinomycin—skin cancer	0.000267	0.000657	CcSEcCtD
Duloxetine—Vomiting—Bleomycin—skin cancer	0.000266	0.000655	CcSEcCtD
Duloxetine—Anaemia—Docetaxel—skin cancer	0.000266	0.000654	CcSEcCtD
Duloxetine—Rash—Bleomycin—skin cancer	0.000264	0.000649	CcSEcCtD
Duloxetine—Dermatitis—Bleomycin—skin cancer	0.000264	0.000649	CcSEcCtD
Duloxetine—Hypersensitivity—Temozolomide—skin cancer	0.00026	0.00064	CcSEcCtD
Duloxetine—Urticaria—Fluorouracil—skin cancer	0.000258	0.000636	CcSEcCtD
Duloxetine—Syncope—Docetaxel—skin cancer	0.000258	0.000635	CcSEcCtD
Duloxetine—Leukopenia—Docetaxel—skin cancer	0.000257	0.000633	CcSEcCtD
Duloxetine—Body temperature increased—Fluorouracil—skin cancer	0.000257	0.000633	CcSEcCtD
Duloxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.000254	0.0209	CbGpPWpGaD
Duloxetine—Palpitations—Docetaxel—skin cancer	0.000254	0.000625	CcSEcCtD
Duloxetine—Asthenia—Temozolomide—skin cancer	0.000253	0.000623	CcSEcCtD
Duloxetine—Loss of consciousness—Docetaxel—skin cancer	0.000253	0.000622	CcSEcCtD
Duloxetine—Cough—Docetaxel—skin cancer	0.000251	0.000617	CcSEcCtD
Duloxetine—Pruritus—Temozolomide—skin cancer	0.00025	0.000614	CcSEcCtD
Duloxetine—Convulsion—Docetaxel—skin cancer	0.000249	0.000613	CcSEcCtD
Duloxetine—Nausea—Bleomycin—skin cancer	0.000248	0.000612	CcSEcCtD
Duloxetine—Hypertension—Docetaxel—skin cancer	0.000248	0.000611	CcSEcCtD
Duloxetine—Vomiting—Dactinomycin—skin cancer	0.000248	0.00061	CcSEcCtD
Duloxetine—Rash—Dactinomycin—skin cancer	0.000246	0.000605	CcSEcCtD
Duloxetine—Chest pain—Docetaxel—skin cancer	0.000245	0.000602	CcSEcCtD
Duloxetine—Arthralgia—Docetaxel—skin cancer	0.000245	0.000602	CcSEcCtD
Duloxetine—Myalgia—Docetaxel—skin cancer	0.000245	0.000602	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000243	0.000598	CcSEcCtD
Duloxetine—Diarrhoea—Temozolomide—skin cancer	0.000241	0.000594	CcSEcCtD
Duloxetine—Hypersensitivity—Fluorouracil—skin cancer	0.00024	0.00059	CcSEcCtD
Duloxetine—Dry mouth—Docetaxel—skin cancer	0.000239	0.000589	CcSEcCtD
Duloxetine—Confusional state—Docetaxel—skin cancer	0.000237	0.000582	CcSEcCtD
Duloxetine—Anaphylactic shock—Docetaxel—skin cancer	0.000235	0.000578	CcSEcCtD
Duloxetine—Oedema—Docetaxel—skin cancer	0.000235	0.000578	CcSEcCtD
Duloxetine—Dizziness—Temozolomide—skin cancer	0.000233	0.000574	CcSEcCtD
Duloxetine—Infection—Docetaxel—skin cancer	0.000233	0.000574	CcSEcCtD
Duloxetine—Nausea—Dactinomycin—skin cancer	0.000232	0.00057	CcSEcCtD
Duloxetine—Shock—Docetaxel—skin cancer	0.000231	0.000568	CcSEcCtD
Duloxetine—Nervous system disorder—Docetaxel—skin cancer	0.00023	0.000566	CcSEcCtD
Duloxetine—Pruritus—Fluorouracil—skin cancer	0.00023	0.000566	CcSEcCtD
Duloxetine—Thrombocytopenia—Docetaxel—skin cancer	0.00023	0.000565	CcSEcCtD
Duloxetine—Tachycardia—Docetaxel—skin cancer	0.000229	0.000564	CcSEcCtD
Duloxetine—Skin disorder—Docetaxel—skin cancer	0.000228	0.000561	CcSEcCtD
Duloxetine—Vomiting—Temozolomide—skin cancer	0.000224	0.000552	CcSEcCtD
Duloxetine—Anorexia—Docetaxel—skin cancer	0.000224	0.00055	CcSEcCtD
Duloxetine—Rash—Temozolomide—skin cancer	0.000223	0.000548	CcSEcCtD
Duloxetine—Diarrhoea—Fluorouracil—skin cancer	0.000222	0.000547	CcSEcCtD
Duloxetine—Dermatitis—Temozolomide—skin cancer	0.000222	0.000547	CcSEcCtD
Duloxetine—Headache—Temozolomide—skin cancer	0.000221	0.000544	CcSEcCtD
Duloxetine—Dizziness—Fluorouracil—skin cancer	0.000215	0.000529	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000214	0.000526	CcSEcCtD
Duloxetine—Insomnia—Docetaxel—skin cancer	0.000212	0.000522	CcSEcCtD
Duloxetine—Paraesthesia—Docetaxel—skin cancer	0.000211	0.000519	CcSEcCtD
Duloxetine—Nausea—Temozolomide—skin cancer	0.00021	0.000516	CcSEcCtD
Duloxetine—Somnolence—Docetaxel—skin cancer	0.000209	0.000513	CcSEcCtD
Duloxetine—Vomiting—Fluorouracil—skin cancer	0.000207	0.000509	CcSEcCtD
Duloxetine—Dyspepsia—Docetaxel—skin cancer	0.000207	0.000508	CcSEcCtD
Duloxetine—Rash—Fluorouracil—skin cancer	0.000205	0.000505	CcSEcCtD
Duloxetine—Dermatitis—Fluorouracil—skin cancer	0.000205	0.000504	CcSEcCtD
Duloxetine—Decreased appetite—Docetaxel—skin cancer	0.000204	0.000502	CcSEcCtD
Duloxetine—Headache—Fluorouracil—skin cancer	0.000204	0.000501	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Docetaxel—skin cancer	0.000203	0.000499	CcSEcCtD
Duloxetine—Fatigue—Docetaxel—skin cancer	0.000202	0.000498	CcSEcCtD
Duloxetine—Pain—Docetaxel—skin cancer	0.000201	0.000494	CcSEcCtD
Duloxetine—Constipation—Docetaxel—skin cancer	0.000201	0.000494	CcSEcCtD
Duloxetine—HTR6—G alpha (s) signalling events—MC1R—skin cancer	0.000197	0.0162	CbGpPWpGaD
Duloxetine—NPY1R—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	0.000195	0.016	CbGpPWpGaD
Duloxetine—NPY1R—GPCR ligand binding—MC1R—skin cancer	0.000194	0.0159	CbGpPWpGaD
Duloxetine—Feeling abnormal—Docetaxel—skin cancer	0.000193	0.000476	CcSEcCtD
Duloxetine—Nausea—Fluorouracil—skin cancer	0.000193	0.000475	CcSEcCtD
Duloxetine—Gastrointestinal pain—Docetaxel—skin cancer	0.000192	0.000472	CcSEcCtD
Duloxetine—Body temperature increased—Docetaxel—skin cancer	0.000186	0.000457	CcSEcCtD
Duloxetine—Abdominal pain—Docetaxel—skin cancer	0.000186	0.000457	CcSEcCtD
Duloxetine—SLC6A4—Circadian rythm related genes—NKX2-1—skin cancer	0.000175	0.0144	CbGpPWpGaD
Duloxetine—Hypersensitivity—Docetaxel—skin cancer	0.000173	0.000425	CcSEcCtD
Duloxetine—Asthenia—Docetaxel—skin cancer	0.000168	0.000414	CcSEcCtD
Duloxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.000167	0.0137	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—RHOU—skin cancer	0.000166	0.0137	CbGpPWpGaD
Duloxetine—Pruritus—Docetaxel—skin cancer	0.000166	0.000409	CcSEcCtD
Duloxetine—Diarrhoea—Docetaxel—skin cancer	0.000161	0.000395	CcSEcCtD
Duloxetine—Dizziness—Docetaxel—skin cancer	0.000155	0.000382	CcSEcCtD
Duloxetine—Vomiting—Docetaxel—skin cancer	0.000149	0.000367	CcSEcCtD
Duloxetine—Rash—Docetaxel—skin cancer	0.000148	0.000364	CcSEcCtD
Duloxetine—Dermatitis—Docetaxel—skin cancer	0.000148	0.000364	CcSEcCtD
Duloxetine—Headache—Docetaxel—skin cancer	0.000147	0.000362	CcSEcCtD
Duloxetine—Nausea—Docetaxel—skin cancer	0.000139	0.000343	CcSEcCtD
Duloxetine—NPY1R—GPCR ligand binding—SHH—skin cancer	0.000138	0.0113	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—PTCH2—skin cancer	0.000138	0.0113	CbGpPWpGaD
Duloxetine—NPY1R—GPCR ligand binding—SMO—skin cancer	0.000131	0.0107	CbGpPWpGaD
Duloxetine—NPY1R—GPCR ligand binding—PTCH1—skin cancer	0.000131	0.0107	CbGpPWpGaD
Duloxetine—HTR6—G alpha (s) signalling events—PTGER4—skin cancer	0.000129	0.0106	CbGpPWpGaD
Duloxetine—NPY1R—GPCR ligand binding—PTGER4—skin cancer	0.000127	0.0105	CbGpPWpGaD
Duloxetine—SLC6A2—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.000123	0.0101	CbGpPWpGaD
Duloxetine—HTR2C—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—NRAS—skin cancer	0.00012	0.00989	CbGpPWpGaD
Duloxetine—HTR6—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	0.00011	0.00899	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—MC1R—skin cancer	0.000109	0.00899	CbGpPWpGaD
Duloxetine—HTR2A—GPCRs, Other—SMO—skin cancer	0.000109	0.00894	CbGpPWpGaD
Duloxetine—SLC6A3—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.000109	0.00892	CbGpPWpGaD
Duloxetine—HTR2A—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—NRAS—skin cancer	0.000105	0.00859	CbGpPWpGaD
Duloxetine—HTR2C—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—KRAS—skin cancer	0.000104	0.00851	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—MC1R—skin cancer	9.94e-05	0.00816	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—PTCH2—skin cancer	9.89e-05	0.00811	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	9.39e-05	0.0077	CbGpPWpGaD
Duloxetine—HTR2A—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—KRAS—skin cancer	9.01e-05	0.00739	CbGpPWpGaD
Duloxetine—HTR2C—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—HRAS—skin cancer	8.82e-05	0.00724	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—PTCH2—skin cancer	8.12e-05	0.00667	CbGpPWpGaD
Duloxetine—HTR2C—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	8.07e-05	0.00662	CbGpPWpGaD
Duloxetine—HTR2A—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—HRAS—skin cancer	7.65e-05	0.00628	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—PTCH2—skin cancer	7.28e-05	0.00598	CbGpPWpGaD
Duloxetine—HTR6—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	7.2e-05	0.00591	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—PTGER4—skin cancer	7.2e-05	0.00591	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—MC1R—skin cancer	7.15e-05	0.00587	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—SHH—skin cancer	7.09e-05	0.00582	CbGpPWpGaD
Duloxetine—HTR2A—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	7.01e-05	0.00575	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	6.91e-05	0.00567	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—SMO—skin cancer	6.72e-05	0.00551	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—PTCH1—skin cancer	6.72e-05	0.00551	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—PTGER4—skin cancer	6.54e-05	0.00537	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—PTCH2—skin cancer	6.32e-05	0.00519	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—SLC12A2—skin cancer	6.23e-05	0.00511	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	6.17e-05	0.00507	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—GLI2—skin cancer	6.16e-05	0.00505	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—RHOU—skin cancer	6.14e-05	0.00504	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	6e-05	0.00493	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—MC1R—skin cancer	5.87e-05	0.00482	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—GLI1—skin cancer	5.79e-05	0.00475	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—SLC12A2—skin cancer	5.52e-05	0.00453	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—SUFU—skin cancer	5.49e-05	0.0045	CbGpPWpGaD
Duloxetine—HTR2C—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	5.3e-05	0.00435	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—MC1R—skin cancer	5.26e-05	0.00432	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—SHH—skin cancer	5.09e-05	0.00418	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—PTCH2—skin cancer	5.07e-05	0.00416	CbGpPWpGaD
Duloxetine—SLC6A4—Circadian rythm related genes—CDK4—skin cancer	4.93e-05	0.00405	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—SMO—skin cancer	4.83e-05	0.00396	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—PTCH1—skin cancer	4.83e-05	0.00396	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—PTGER4—skin cancer	4.7e-05	0.00386	CbGpPWpGaD
Duloxetine—HTR2A—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	4.61e-05	0.00378	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—MC1R—skin cancer	4.57e-05	0.00375	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	4.55e-05	0.00373	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—RHOU—skin cancer	4.52e-05	0.00371	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—SHH—skin cancer	4.19e-05	0.00344	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—RASA1—skin cancer	4.16e-05	0.00341	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—MC1R—skin cancer	4.04e-05	0.00332	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—SMO—skin cancer	3.97e-05	0.00326	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—PTCH1—skin cancer	3.97e-05	0.00326	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	3.95e-05	0.00324	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—RHOU—skin cancer	3.92e-05	0.00322	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—PTGER4—skin cancer	3.86e-05	0.00317	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—SHH—skin cancer	3.75e-05	0.00308	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—PTCH2—skin cancer	3.74e-05	0.00307	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—MC1R—skin cancer	3.67e-05	0.00301	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—PTCH1—skin cancer	3.56e-05	0.00292	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—SMO—skin cancer	3.56e-05	0.00292	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—skin cancer	3.47e-05	0.00285	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—PTGER4—skin cancer	3.46e-05	0.00284	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—FOXO4—skin cancer	3.41e-05	0.0028	CbGpPWpGaD
Duloxetine—SLC6A3—Transmission across Chemical Synapses—BRAF—skin cancer	3.34e-05	0.00274	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—SHH—skin cancer	3.26e-05	0.00267	CbGpPWpGaD
Duloxetine—CYP1A2—Arachidonic acid metabolism—PTGS2—skin cancer	3.24e-05	0.00266	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PTCH2—skin cancer	3.24e-05	0.00266	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—PTCH1—skin cancer	3.09e-05	0.00253	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—SMO—skin cancer	3.09e-05	0.00253	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—PTGER4—skin cancer	3.01e-05	0.00247	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PTCH2—skin cancer	3e-05	0.00246	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—MC1R—skin cancer	2.97e-05	0.00244	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—MC1R—skin cancer	2.7e-05	0.00222	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—skin cancer	2.7e-05	0.00222	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—PTGER4—skin cancer	2.66e-05	0.00218	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—SHH—skin cancer	2.61e-05	0.00215	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—MC1R—skin cancer	2.58e-05	0.00212	CbGpPWpGaD
Duloxetine—SLC6A3—Neuronal System—BRAF—skin cancer	2.56e-05	0.0021	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—PTCH1—skin cancer	2.48e-05	0.00203	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—SMO—skin cancer	2.48e-05	0.00203	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	2.43e-05	0.00199	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—PTGER4—skin cancer	2.41e-05	0.00198	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—IL6—skin cancer	2.35e-05	0.00193	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—MC1R—skin cancer	2.35e-05	0.00193	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—skin cancer	2.32e-05	0.00191	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—TERT—skin cancer	2.28e-05	0.00187	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—GLI2—skin cancer	2.27e-05	0.00186	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PTCH2—skin cancer	2.21e-05	0.00181	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MC1R—skin cancer	2.17e-05	0.00178	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—GLI1—skin cancer	2.14e-05	0.00175	CbGpPWpGaD
Duloxetine—SLC6A4—Circadian rythm related genes—TP53—skin cancer	2.1e-05	0.00172	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—SUFU—skin cancer	2.02e-05	0.00166	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—skin cancer	1.97e-05	0.00162	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—PTGER4—skin cancer	1.96e-05	0.00161	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—SHH—skin cancer	1.92e-05	0.00158	CbGpPWpGaD
Duloxetine—SLC6A4—Circadian rythm related genes—IL6—skin cancer	1.92e-05	0.00158	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—NRAS—skin cancer	1.92e-05	0.00158	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PTCH2—skin cancer	1.92e-05	0.00157	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—PTCH1—skin cancer	1.82e-05	0.0015	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—SMO—skin cancer	1.82e-05	0.0015	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—BRAF—skin cancer	1.8e-05	0.00148	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	1.8e-05	0.00148	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—PTGER4—skin cancer	1.78e-05	0.00146	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—PTGER4—skin cancer	1.7e-05	0.00139	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—GLI2—skin cancer	1.67e-05	0.00137	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—SHH—skin cancer	1.67e-05	0.00137	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—KRAS—skin cancer	1.65e-05	0.00136	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MC1R—skin cancer	1.6e-05	0.00131	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PTCH1—skin cancer	1.58e-05	0.0013	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—SMO—skin cancer	1.58e-05	0.0013	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—GLI1—skin cancer	1.57e-05	0.00129	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	1.57e-05	0.00128	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	1.55e-05	0.00127	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—SHH—skin cancer	1.54e-05	0.00127	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PTGER4—skin cancer	1.54e-05	0.00127	CbGpPWpGaD
Duloxetine—SLC6A3—Transmission across Chemical Synapses—HRAS—skin cancer	1.54e-05	0.00126	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—RASA1—skin cancer	1.53e-05	0.00126	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—SUFU—skin cancer	1.49e-05	0.00122	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—SMO—skin cancer	1.46e-05	0.0012	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PTCH1—skin cancer	1.46e-05	0.0012	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—GLI2—skin cancer	1.45e-05	0.00119	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PTGER4—skin cancer	1.42e-05	0.00117	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—IL6—skin cancer	1.42e-05	0.00116	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—HRAS—skin cancer	1.4e-05	0.00115	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MC1R—skin cancer	1.39e-05	0.00114	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—GLI1—skin cancer	1.37e-05	0.00112	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	1.35e-05	0.00111	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—IL6—skin cancer	1.34e-05	0.0011	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	1.32e-05	0.00108	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SUFU—skin cancer	1.29e-05	0.00106	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PLIN2—skin cancer	1.28e-05	0.00105	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	1.26e-05	0.00104	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—FOXO4—skin cancer	1.26e-05	0.00103	CbGpPWpGaD
Duloxetine—SLC6A3—Neuronal System—HRAS—skin cancer	1.18e-05	0.000966	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	1.15e-05	0.00094	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—SHH—skin cancer	1.14e-05	0.000933	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—NRAS—skin cancer	1.13e-05	0.000931	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—RASA1—skin cancer	1.13e-05	0.000927	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	1.1e-05	0.0009	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PLIN2—skin cancer	1.08e-05	0.000888	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PTCH1—skin cancer	1.08e-05	0.000885	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—SMO—skin cancer	1.08e-05	0.000885	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PTGER4—skin cancer	1.05e-05	0.000861	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CSPG4—skin cancer	1.03e-05	0.000845	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SHH—skin cancer	9.87e-06	0.00081	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—RASA1—skin cancer	9.81e-06	0.000805	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—KRAS—skin cancer	9.76e-06	0.000801	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PTCH1—skin cancer	9.36e-06	0.000768	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SMO—skin cancer	9.36e-06	0.000768	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—FOXO4—skin cancer	9.27e-06	0.000761	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PTGER4—skin cancer	9.11e-06	0.000748	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CSPG4—skin cancer	8.72e-06	0.000716	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—TP53—skin cancer	8.68e-06	0.000712	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TERT—skin cancer	8.41e-06	0.00069	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—HRAS—skin cancer	8.3e-06	0.000681	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—FOXO4—skin cancer	8.05e-06	0.000661	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—IL6—skin cancer	7.94e-06	0.000652	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—NRAS—skin cancer	7.08e-06	0.000581	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ENO2—skin cancer	7e-06	0.000575	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—BRAF—skin cancer	6.66e-06	0.000546	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TERT—skin cancer	6.19e-06	0.000508	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—KRAS—skin cancer	6.1e-06	0.0005	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ENO2—skin cancer	5.93e-06	0.000487	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TERT—skin cancer	5.38e-06	0.000441	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—NRAS—skin cancer	5.22e-06	0.000428	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—HRAS—skin cancer	5.18e-06	0.000425	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—IL6—skin cancer	4.96e-06	0.000407	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—BRAF—skin cancer	4.9e-06	0.000402	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	4.64e-06	0.000381	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—NRAS—skin cancer	4.53e-06	0.000372	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—KRAS—skin cancer	4.49e-06	0.000368	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—BRAF—skin cancer	4.26e-06	0.000349	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NRAS—skin cancer	4.18e-06	0.000343	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ERCC2—skin cancer	4.07e-06	0.000334	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—KRAS—skin cancer	3.9e-06	0.00032	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—HRAS—skin cancer	3.82e-06	0.000313	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—IL6—skin cancer	3.65e-06	0.0003	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—KRAS—skin cancer	3.6e-06	0.000296	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ERCC2—skin cancer	3.44e-06	0.000283	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—HRAS—skin cancer	3.31e-06	0.000272	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TP53—skin cancer	3.2e-06	0.000263	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—IL6—skin cancer	3.17e-06	0.00026	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NRAS—skin cancer	3.08e-06	0.000253	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—HRAS—skin cancer	3.06e-06	0.000251	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IL6—skin cancer	2.93e-06	0.00024	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NRAS—skin cancer	2.68e-06	0.00022	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—KRAS—skin cancer	2.65e-06	0.000218	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PTGS2—skin cancer	2.44e-06	0.0002	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TP53—skin cancer	2.36e-06	0.000193	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—KRAS—skin cancer	2.3e-06	0.000189	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HRAS—skin cancer	2.25e-06	0.000185	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IL6—skin cancer	2.16e-06	0.000177	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PTGS2—skin cancer	2.07e-06	0.00017	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TP53—skin cancer	2.05e-06	0.000168	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—HRAS—skin cancer	1.96e-06	0.000161	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IL6—skin cancer	1.87e-06	0.000154	CbGpPWpGaD
